Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg

Inclusion Criteria: * Male volunteers in the age between 20 and 45 years old * Body Mass Index (BMI) in the range of 19 to 27 kg/m2 Exclusion Criteria: * History of allergy or sensitivity to any drug, including amlodipine or valsartan * History of clinically significant hepatic, renal, gastrointestinal, neurology, pulmonary, endocrine, musculoskeletal, hematologic, oncologic, psychiatric, especially cardiovascular disease * History of surgery except or gastrointestinal diseases which might significantly change absorption of medicines * Hypotension (Systolic Blood Pressure(SBP) ≤ 100 mmHg or Diastolic Blood Pressure(DBP) ≤ 65 mmHg) * Hypertension (SBP ≥ 150 mmHg or DBP ≥ 95 mmHg) * Clinical laboratory test values are outside the accepted normal range * Aspartate Transaminase(AST) or Alanine Transaminase(ALT) \> 1.25 times to normal range * Total bilirubin \> 1.25 times to normal range * Positive for Hepatitis B Virus surface Antigen(HBsAg), Hepatitis C Virus Antibody(HCVAb) or Human Immunodeficiency Virus Antibody(HIVAb)